Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"GNI Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"GNI Group","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Biosciences Completes First Steps in Reverse Merger Plan","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Beijing Continent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Biosciences Announces Completion of Business Combination with Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydronidone

    Menu

    Hydronidone

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Gyre Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Catalyst Biosciences Announces Completion of Business Combination with Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

              Details:

              The combined company will more efficiently conduct clinical research and development of their promising pipeline of product candidates in organ fibrosis and inflammatory diseases, including F351 (hydronidone) for liver fibrosis.

              Lead Product(s): Hydronidone

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: F351

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Beijing Continent Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger October 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GNI Group

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Catalyst Biosciences Completes First Steps in Reverse Merger Plan

              Details:

              F351 is a next-generation pirfenidone analog in Phase 3 clinical development for the treatment of HBV associated liver fibrosis in China and the combined company expects to file an IND in the US and commence Phase 2 studies in 2023.

              Lead Product(s): Hydronidone

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Catalyst Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              GNI Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China

              Details:

              F351 was generally well tolerated in this study. In patients treated with placebos, 60 mg/tid F351, 90 mg/tid F351, and 120 mg/tid F351, respectively.

              Lead Product(s): Hydronidone,Entecavir

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY